Tonix Pharmaceuticals Announces In-Licensing Of TNX-4800 Monoclonal Antibody For Annual Lyme Disease Prevention Across US Endemic Regions

Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic: pharmacodynamic: efficacy relationship (1: 1: 1)

Planning adaptive Phase 2/3 study Approximately 70 million people that are eligible for treatment live in areas of the U.S. in which Lyme Disease is endemic